Coldrex Now Available from Hemofarm

Hemofarm, which operates within STADA Group, expands its portfolio of Consumer Healthcare products in Serbia, and now offers Coldrex, one of a well-known products for relieving flue and cold symptoms. This product has previously been available in the markets of Central and Eastern Europe within the offer of GlaxoSmithKline, while in the future it will be a part of the STADA and Hemofarm product range.

During the previous period, STADA significantly expanded its operations in the field of OTC segment, including last year's acquisition of a part of the GlaxoSmithKline (GSK) portfolio, which was already present in many European countries, including Serbia. In addition to products intended for the treatment of cold and flu symptoms, this acquisition also included the takeover of GSK brands in the field of skin care, treatment of venous diseases, a range of products used for treating sore throat, etc. Coldrex portfolio that will be available in Serbia comprises several products in various forms: Coldrex HotRem Lemon in sachets, Coldrex MaxGrip Forest Fruit also in sachets, and Coldrex in the form of tablets.

Coldrex od sada u ponudi Hemofarma

‘The acquisition of established branded products from GSK has strengthened our position as a leading player in the global consumer healthcare segment. I am pleased that we are now officially taking over the marketing of these high-quality products in our core markets such as Serbia and are thus once again fulfilling our mission of caring for people's health as a trusted partner’, said STADA CEO Peter Goldschmidt.

According to Hemofarm’s CEO Ronald Seeliger, Hemofarm's already rich range of OTC products has now been further enhanced by the well-known Coldrex brand.

‘We have expanded our portfolio with another quality and well-known product in Serbia and region-wide, and we expect Coldrex, under our leadership, to maintain a high position among preparations indicated for relieving cold and flu symptoms. In addition to the fact that in the pandemic circumstances we are maximally focused on the production and regular supply of the market with medicinal products used in the treatment of COVID19 and chronic diseases, this is also an indicator of our commitment to simultaneous expanding the segment of CHC products for other milder indications. Besides launching new medicinal products and preparations, the development of our portfolio also includes taking over such products of other successful brands, while following the modern global therapeutic protocols’, the CEO of Hemofarm pointed out on this occasion.